Latest News and Press Releases
Want to stay updated on the latest news?
-
BOULDER, Colo., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology focused on the discovery and development of next-generation...
-
Company on track to deliver initial proof of concept data for ELVN-001 and ELVN-002 in 2024 Strong balance sheet, closing the quarter with $263 million in cash, cash equivalents and marketable...
-
Continued progress of parallel lead programs, ELVN-001 and ELVN-002, through dose escalation in Phase 1 trials, with initial proof of concept data for both programs expected in 2024 Strong balance...
-
BOULDER, Colo., May 31, 2023 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of...
-
Successfully completed merger with Imara Inc., trading under the new ticker symbol on Nasdaq, “ELVN” Dosed first patient in Phase 1 study of ELVN-002 in patients with HER2-altered non-small cell...
-
Combined company will be focused on advancing Enliven’s clinical-stage pipeline of precision oncology programs Shares to trade on Nasdaq under the new ticker symbol “ELVN” on February 24, 2023 ...